ADV6209 for Premedication in Pediatric Anesthesia: A Double-Blinded, Randomized Controlled Trial

Area of Science:

• Anesthesiology
• Pediatric Pharmacology
• Clinical Trial Methodology

Background:

• Midazolam is a common sedative for pediatric premedication.
• Anxiety and poor oral acceptance of oral midazolam can complicate anesthesia induction.
• ADV6209 is a novel oral midazolam formulation with γ-cyclodextrin.

Purpose of the Study:

• To compare the clinical efficacy and oral acceptance of ADV6209 versus conventional midazolam for pediatric premedication.
• To evaluate the impact on anxiety, oral acceptance, and facemask acceptance before anesthesia.
• To assess the safety profile of ADV6209 in pediatric patients.

Main Methods:

• Randomized, double-blinded controlled trial involving 80 children (2-8 years, ASA I/II).
• Children received either conventional midazolam or ADV6209 (0.25 mg/kg).
• Anxiety assessed using the modified Yale Preoperative Anxiety Scale-Short Form (mYPAS-SF); oral and facemask acceptance also scored.

Main Results:

• No significant difference in mYPAS-SF anxiety scores between groups at 30 minutes post-administration.
• ADV6209 demonstrated significantly better oral acceptance (100% vs. 85%, p=0.037).
• Both formulations were effective in reducing anxiety and providing sedation; no adverse events reported.

Conclusions:

• ADV6209 is as effective as conventional midazolam in reducing preoperative anxiety in children.
• ADV6209 offers improved oral acceptance, potentially simplifying pediatric premedication.
• This formulation may reduce off-label drug use and improve the pre-anesthetic experience for young children.